RxDoctor Payments DataLook up a doctor →

Audra Marcum

Acute Care · Lexington, KYNPI 1497703987

Payments from drug & device makers

$13,685in general payments, 2019–2025

Across 772 payments — averaging $17.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • Boehringer Ingelheim$2K
  • AstraZeneca$998
  • Grifols USA, LLC$945
  • Sanofi$855
  • Regeneron Healthcare Solutions, Inc.$676
  • plus $6K from 35 others

What the payments were for

  • Food & beverage$13,54099%
  • Education$1441%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,685 in reported general payments places this provider in the 95th percentile of 319 acute care providers in Kentucky.

See all acute care providers in Kentucky

Medicare billing

Part B allowed, 2024
$91,838
Medicare patients
394
Services billed
1,319

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate37$487,543
Trelegy ElliptaFluticasone/Umeclidin/Vilanter444$413,553
NucalaMepolizumab56$221,148
Dupixent PenDupilumab38$141,678
Fasenra PenBenralizumab20$113,142
Dupixent SyringeDupilumab26$111,606
Breztri AerosphereBudesonide/Glycopyr/Formoterol129$108,415
Spiriva RespimatTiotropium Bromide79$64,732
Stiolto RespimatTiotropium Br/Olodaterol Hcl89$61,226
Breo ElliptaFluticasone/Vilanterol99$55,668
Advair HfaFluticasone Propion/Salmeterol58$26,869
SymbicortBudesonide/Formoterol Fumarate52$19,251
DuleraMometasone/Formoterol24$18,884
Spiriva HandihalerTiotropium Bromide13$16,594
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr25$16,369

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$2,112$713,821644 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$2,001$613,501205 claims
AstraZenecaBreztri Aerosphere, Symbicort$998$127,667181 claims
MerckDulera$72$18,88424 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$13$5,33819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 319 acute care providers in Kentucky.

Other acute care in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →